Safety Study of HSV2 DNA Vaccine to Treat Patients With Recurrent Genital Herpes Caused by HSV-2
Completed · Phase 1
Conditions studied: HSV-2
In brief
The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing. The study will also test the ability of vaccine to cause particular immune responses in the body and evaluate the effect it has on herpes outbreaks
Key facts
- Study ID
- NCT00274300
- Run by
- PowderMed
- People needed
- 36
- Starts
- 2004-08-01
- Expected to finish
- 2005-07-01
- Last updated by the study team
- 2007-01-29
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Westover Heights Clinic — Portland, Oregon, United States
- Center for Clinical Studies — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.